Ready to learn if Semaglutide or Tirzepatide is right for you
The lawsuits allege that Novo Nordisk: Failed to adequately warn about the risk of severe gastrointestinal conditions like gastroparesis or vision loss Knew or should have known about these risks based on how semaglutide works in the body Continued to aggressively market the drug without properly disclosing these risks Failed to conduct sufficient long-term studies on gastrointestinal effects The FDA updated Ozempics warning label in September 2023 after receiving multiple reports of intestinal blockages
Nevi vary in size, shape, surface characteristics, and color
Novo Nordisks patent on semaglutide expired in several large countries in March, clearing the way for cheaper generic alternatives that could make GLP-1s attainable for many more people globally
Under draft NICE recommendations currently out for consultation, GPs will be able to prescribe tirzepatide for weight loss, marking a shift from guidance on semaglutide for weight loss that said it should only be available through specialist provision
Personalization based on genetics can shorten trial-and-error and improve your treatment confidence
